Evaluation the efficacy of Achillea wilhelmsii capsule in ulcerative colitis patients
- Conditions
- ulcerative colitis.Ulcerative colitis, unspecified
- Registration Number
- IRCT2016102620071N2
- Lead Sponsor
- Vice Chancellor for Research, Kermanshah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 44
age>18- ability to swallow the capsule- patients who sign the testimonials and cooperate during the study.(In cases which patients do not have education,the investigator should read the testimonial for them.if they are satisfied, the investigator can include them to the study.)- patients who are not cured with Achillea wilhelmsii during a last month.-Patients who their diseases are approved by complete medical evaluation, colonoscopy, pathology and laboratory data.-Only patients with mild to moderate ulcerative colitis can be include to this study. Exclusion criteria:smokers-pregnant patients and nursing mothers-patients who have to use other drugs that interference with this medication (such as systemic NSAID, antihistamins or systemic antibiotics during last 2 weeks)- patients who are suffering from other diseases in addition to ulcerative colitis that the etiology of them are oxidative stress, such as metabolic syndrome, diabetic leg ulcer, coronary arterial disease, pulmonary infection, patients who are disposed to a serious health danger, such as severe cardiac, liver or renal diseases.- If significant side effects occur, the patient will be excluded from the study and followed to end of the study.- If a patient do not want to continue to cooperating for any reasons, he will be excluded from the study.- patients with severe allergy to this plant (dermatitis contact) will be excluded.
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of excretion daily. Timepoint: before using the drug-2 weeks after using the drug-30 days after using the drugs. Method of measurement: based on Mayo clinic questionary and ESR,CBC,CRP.;Rate of rectal bleeding. Timepoint: before using the drug-2 weeks after using the drug-30 days after using the drugs. Method of measurement: based on Mayo clinic score, CRP, CBC, and ESR.
- Secondary Outcome Measures
Name Time Method Photo sensitivity- gastrointestinal disorders. Timepoint: Two weeks after using the drug- 30 days after using the drug. Method of measurement: based on side effect questionary.